Almirall and Galapagos enter research alliance
0
* Three-year integrated drug discovery alliance is for identifying drug
development candidates for treating respiratory disease
* The value of this collaboration could reach EUR7.5 million
Barcelona (Spain) and Mechelen (Belgium); 25 January 2012 - Almirall, S.A.
(ALM.MC) announced today that has formed a research alliance with BioFocus, an
affiliate from Galapagos NV (Euronext: GLPG).
The three-year alliance is aimed at delivering drug development candidates
directed to a key respiratory target of interest to Almirall. Under the terms
of the collaboration, BioFocus will apply its integrated drug discovery
capabilities whilst Almirall will bring in respiratory specific knowhow to the
joint experimental effort. The value of this collaboration to BioFocus could
reach EUR7.5 million.
"We selected BioFocus for this alliance because of the excellent technology and
scientific fit between both companies, " said Dr. Bertil Lindmark, CSO, Executive
Director R&D of Almirall.
"We are delighted to form a drug discovery alliance with one of Europe´s leading
research-based pharmaceutical companies, " added Dr. Chris Newton, SVP Galapagos
Services and Managing Director, BioFocus.
Respiratory is a key research focus for Almirall together with gastrointestinal
and dermatology areas where the company is especially engaged to offer new
therapeutic solutions.
About Almirall
Almirall is an international pharmaceutical company based on innovation and
committed to health. Headquartered in Barcelona, Spain, it researches, develops,
manufactures and commercialises its own R&D and licensed drugs with the aim of
improving people´s health and wellbeing.
Almirall focuses its research resources on therapeutic areas related to the
treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease),
gastrointestinal disorders, psoriasis and other dermatological conditions.
Almirall´s products are currently present in over 70 countries while it has
direct presence in Europe and Latin America through 12 affiliates.
For further information please visit the website at: www.almirall.com
About BioFocus
BioFocus provides integrated drug discovery that delivers pre-clinical drug
candidates in all therapeutic areas with strong capability in neurodegenerative
diseases, inflammatory diseases and with a growing track record of delivering
candidates against rare and neglected diseases. BioFocus has advanced and
comprehensive drug discovery capabilities that are applied to client projects to
deliver targets, hits, leads and candidate pre-clinical drugs. The company
employs over 220 exceptionally qualified and industry experienced scientists at
its three research centers in the UK, Switzerland and the Netherlands.
Since its foundation in 1997, BioFocus has striven to produce high quality data
for its clients and this quality is assured by ISO9001 qualification validated
by regular, independent inspection of all BioFocus research centers. For more
information visit: www.biofocus.com
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company
specialized in the discovery and development of small molecule and antibody
therapies with novel modes-of-action. The Company is progressing GLPG0634, as
well as one of the largest pipelines in biotech, with seven programs in
development and over 50 discovery programs. The Galapagos Group has about 800
employees and operates facilities in six countries, with global headquarters in
Mechelen, Belgium. More info at: www.glpg.com
More information:
Ketchum Pleon
Sonia San Segundo
Tel.: +34 91 788 32 00
sonia.sansegundo@ketchumpleon.com
Galapagos NV
Chris Newton, SVP Services
Tel: +44 1799 533535
ir@glpg.com
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes, " "anticipates, "
"expects, " "intends, " "plans, " "seeks, " "estimates, " "may, " "will, " "could, "
"stands to, " and "continues, " as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1579895]
BE0003818359
